Novartis antibody increases muscle growth in mice and human cell cultures
The Novartis antibody bimagrumab (BYM338) boosted muscle mass and function in laboratory experiments, according to a scientific paper in Molecular Cell Biology. The paper demonstrates the activity of the compound in cell and mouse models and its mechanism of action.
New Malaria Target, PI4K, Published in Nature
Malaria kills more than 660,000 people each year, mostly African children. Novartis scientists have discovered a new drug target for treating malaria. The discovery, published online in Nature, identifies phosphatidylinositol-4 kinase (PfPI4K) as the target of the imidazopyrazines, a novel experimental compound class that inhibits the development of multiple malaria-causing Plasmodium species at each stage of infection in the human host.
Visonary Leaders Changing the Practice of Medicine
NIBR researchers Drs. Anthony Boitano, Darrin Stuart, and Estelle Trifilieff live in different cities, work on different diseases, but share a common goal to Change the Practice of Medicine. Learn more about what they are working on and what motivates them in these videos.
Novartis ranked among Science’s top employers
Novartis is one of this year’s top 20 employers in an annual survey from Science.
Letters To My Younger Self - Jennifer Leeds
“You’ve been brainwashed. You’re literally unable to consider yourself successful if you don’t ultimately end up in academia.” A NIBR scientist writes to herself, noting the signs of great accomplishment, both as a scientist and a leader.
Harnessing a Unique Moment in Neuroscience
NIBR's new Neuroscience team will leverage the latest advances in human genetics to probe the underlying pathophysiology of neuropsychiatric and neurodegenerative diseases. NIBR hopes to hire 30 associates by the end of 2013 and 70 more over the next three years. The goal is to harness the recent explosion of neuroscience knowledge and technology to help patients.
BYM338 in Sporadic Inclusion Body Myositis (sIBM)
Novartis announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338- bimagrumab- for sporadic inclusion body myositis (sIBM). Named after Bhima - the Hindu God of Strength and Stature, BYM338 is expected to enter clinical trials this fall. Only 11,000 people worldwide suffer from a disease that leaves many in a wheelchair within 15 years. While a rare disease, it is the most common degenerative disease of muscle in adults older than 65 years.
Letters To My Younger Self - Susan Gasser
“It’s proving very hard to have a career and a family. You have no female colleagues. All of the women you know have dropped their careers. I’m writing to tell you to do it anyway.” A leading science researcher writes to her younger self at age 35, shortly after managing to settle her boy in kindergarten in Switzerland.
Novartis and India’s Biological E sign typhoid and paratyphoid licensing agreement
Novartis has signed a licensing agreement with Biological E to manufacture and distribute two vaccines to protect against typhoid and paratyphoid fevers. The Novartis Institute for Global Health (NVGH) with assistance from foundations says both could reduce the burden of both diseases in endemic regions.
Researchers look for ways to delay Huntington’s Disease Onset
Huntingtons is a genetic disorder in which nerve cells in certain parts of the brain degenerate due to a buildup of mutant protein encoded by the HTT gene. No cure is available. One possible therapeutic intervention is to reduce or delay the buildup of too much resulting HTT protein. NIBR researchers developed the first genome-wide screen to identify modulators of HTT protein level and test a potential intervention, reducing the amount of cell death in mouse and human neurons. While much more work needs to be done, the Nature Neuroscience paper offers hope for delaying or reducing symptoms of this terrible disease.
Next Generation Sequencing (NGS) and new analysis techniques help identify Theiler’s disease-associated virus (TDAV) in horses
The new Exploratory Virology group with Infectious Disease in Emeryville, CA was charged with finding previously unknown viruses that cause disease. To do this they needed access to epidemiologic data, well documented samples and collaborators who would work with them. The Theiler's disease project came to them through the Cornell Veterinary School and provided a perfect opportunity to develop their methods and to investigate a 100-year-old mystery.
Rare Disease Research at NIBR
Rare disorders targeted by investigational compounds from Novartis include Netherton and Cushings Diseases, Fragile X Syndrome, spinal muscular atrophy, and Cowden and Gorlin’s Syndromes.
Ghanaian and Novartis researchers build scientific bridges
Building connections between NIBR and African scientists and medical communities is critical to solving major health problems that impact millions of people in Africa. By building scientific and medical capabilities in these countries, local scientists and physicians can more effectively address the health of their own populations. One effort is underway with University of Science and Technology (KNUST) in Kumasi, Ghana.